Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer files riociguat for CTEPH and PAH in US and EU

This article was originally published in Scrip

Executive Summary

Bayer has filed for approval in the US and EU for its oral soluble guanylate cyclase (sGC) stimulator riociguat for two forms of pulmonary hypertension. The company had planned the filings for the first half of 2013 following positive results in the two indications, chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PAH), both rare but life-threatening diseases. While there are approved therapies for PAH, the prognosis is poor. There are no currently approved drugs available for CTEPH.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts